Asymmetrically branched degradable polyethylene glycol derivatives

A branched degradable polyethylene glycol derivative with an oligopeptide structure addresses the issue of cell vacuoles by maintaining blood stability and degrading within cells, enhancing the efficacy of biological substance modifications.

JP7587788B2Active Publication Date: 2024-11-21NOF CORP +1
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
JP2020160392
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-09-26
Filing Date
2020-09-25
Publication Date
2024-11-21
Estimated Expiration
2040-09-25

AI Technical Summary

Technical Problem

Existing high-molecular-weight polyethylene glycol derivatives used to modify biological substances can cause cell vacuoles when administered in high doses over long periods, and there is a need for branched, degradable polyethylene glycol derivatives that maintain blood stability and degrade within cells to prevent this issue.

Method used

Development of a branched degradable polyethylene glycol derivative with an oligopeptide moiety that is stable in the blood and decomposed by intracellular enzymes, featuring specific molecular weights and functional groups for effective modification and degradation.

Benefits of technology

The branched degradable polyethylene glycol derivative provides extended blood half-life for modified biological substances while preventing cell vacuoles, ensuring stability in the bloodstream and efficient intracellular degradation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007587788000001
    Figure 0007587788000001
  • Figure 0007587788000002
    Figure 0007587788000002
  • Figure 0007587788000003
    Figure 0007587788000003
Patent Text Reader

Abstract

To provide a high-molecular-weight branched, degradable polyethylene glycol derivative which does not cause cell vacuoles.SOLUTION: A branched, degradable polyethylene glycol derivative represented by formula (1) includes an oligopeptide that decomposes intracellularly in each molecule. (In the formula, k1 and k2 are independently 1-12; j1 and j2 are independently 45-950; R is a hydrogen atom, a substituted or unsubstituted C1-12 alkyl group, a substituted aryl group, an aralkyl group, or a heteroalkyl group; Z is an oligopeptide which is degraded by intracellular enzymes; X is a functional group which can react with a biological substance; and L1 and L2 are each independently single bonds or divalent spacers).SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a branched degradable polyethylene glycol derivative which is degradable within cells and is used for modifying biologically relevant substances. [Background technology]

[0002] When drugs using bio-related substances such as hormones, cytokines, antibodies, and enzymes are administered to the body, they are usually quickly excreted from the body by glomerular filtration in the kidneys or uptake by macrophages in the liver and spleen. Therefore, their half-life in the blood is short, and it is often difficult to obtain sufficient pharmacological effects. To solve this problem, attempts have been made to chemically modify bio-related substances with hydrophilic polymers such as sugar chains and polyethylene glycol, albumin, etc. As a result, it is possible to extend the half-life in the blood of bio-related substances by increasing the molecular weight and forming a hydration layer. It is also well known that modification with polyethylene glycol can reduce the toxicity and antigenicity of bio-related substances and improve the solubility of poorly water-soluble drugs.

[0003] Biomaterials modified with polyethylene glycol are covered with a hydration layer formed by hydrogen bonds between the ether bonds of polyethylene glycol and water molecules, and the molecular size increases, allowing them to avoid glomerular filtration in the kidney. It is also known that the interaction with opsonins and the cell surfaces that make up each tissue is reduced, reducing migration to each tissue. Polyethylene glycol is an excellent material for extending the half-life of biomaterials in the blood, and it is known that its performance is more effective the larger the molecular weight. Many studies have been conducted on biomaterials modified with high molecular weight polyethylene glycol with a molecular weight of 40,000 or more, and the results show that the blood half-life can be significantly extended.

[0004] Polyethylene glycol is considered the gold standard among modifiers used to improve the performance of biomaterials, and currently, several polyethylene glycol-modified preparations are on the market and used in medical practice. On the other hand, in 2012, the European Medicines Agency (EMA) reported that when a biomaterial modified with a high molecular weight polyethylene glycol having a molecular weight of 40,000 or more is administered to an animal for a long period of time at a certain dose or more, vacuoles are generated in the cells of some tissues (Non-Patent Document 1). At present, there are no reports that the generation of vacuoles itself has a negative effect on the human body, and considering that the dose used in the previous EMA report is extremely high compared to the dose generally applied in medical practice, it can be said that the safety of therapeutic preparations modified with polyethylene glycol having a molecular weight of 40,000 or more that are currently manufactured and sold is not a problem. However, in the treatment of very special diseases (e.g., dwarfism, etc.), it can be assumed that a treatment protocol in which a polyethylene glycol-modified preparation is administered to a patient in a high dose for a long period of time will be adopted. Therefore, it is expected that there is a potential demand for the development of a polyethylene glycol-modified preparation that is applicable even in such special situations and does not generate vacuoles in cells.

[0005] In Non-Patent Document 2, when a large excess amount of polyethylene glycol was administered alone to animals over a long period of time compared with the dosage of a normal polyethylene glycol-modified preparation, no vacuoles were observed at a molecular weight of 20,000, but the occurrence of vacuoles was confirmed at a molecular weight of 40,000. One possible means of suppressing vacuoles is to reduce the molecular weight of polyethylene glycol, but reducing the molecular weight causes the problem that the half-life in the blood of biologically relevant substances cannot be sufficiently improved.

[0006] There are reports of a technique for decomposing high molecular weight polyethylene glycol into low molecular weight polyethylene glycol in the body and promoting excretion from the kidney. Patent Document 1 describes a polyethylene glycol derivative having a sulfide bond or peptide bond site that is cleaved in the body. It describes that the polyethylene glycol derivative is decomposed in the body to a molecular weight suitable for excretion from the kidney. However, no data on specific decomposition is shown, and there is no data on promotion of excretion from the kidney. Furthermore, there is no description of cell vacuoles.

[0007] Patent Document 2 describes a polyethylene glycol derivative having an acetal moiety that can be hydrolyzed in a low pH environment in the body. It is described that the polyethylene glycol derivative is decomposed in the body to a molecular weight suitable for excretion from the kidney. However, there is no data that specifically shows that excretion from the kidney is promoted, and there is no description of cell vacuoles. In addition, it is known that these hydrolyzable acetal moieties are gradually decomposed in the blood, and it is expected that the blood half-life of the modified biological substance cannot be sufficiently improved.

[0008] On the other hand, there have been reports of polyethylene glycol derivatives incorporating degradable oligopeptides for effective drug release, and hydrogels that degrade in the body.

[0009] Non-Patent Document 3 describes a polyethylene glycol derivative having an oligopeptide moiety that is degraded by an enzyme. Here, the oligopeptide is introduced as a linker between the anticancer drug and the polyethylene glycol, and it is reported that the oligopeptide is degraded by an enzyme specifically expressed around the tumor, efficiently releasing the anticancer drug. The purpose is the release of the anticancer drug, and the degradability is not imparted to the polyethylene glycol for the purpose of suppressing cell vacuoles.

[0010] Non-Patent Document 4 describes a hydrogel using a crosslinking molecule having an oligopeptide moiety that is degraded by an enzyme and a multi-branched polyethylene glycol derivative. Here, the oligopeptide is used as a crosslinking molecule that connects the multi-branched polyethylene glycol derivative, and can further impart enzymatic degradability to the hydrogel. The purpose is to prepare a degradable hydrogel, not to impart degradability to polyethylene glycol for the purpose of suppressing cell vacuoles.

[0011] Patent Document 3 describes a branched polyethylene glycol derivative having an oligopeptide skeleton. Here, the oligopeptide is used as the basic skeleton of the polyethylene glycol derivative, and is not used to impart enzymatic decomposition. The oligopeptide is characterized by containing amino acids having amino or carboxyl groups in the side chain, such as lysine and aspartic acid, and the purpose is to synthesize a branched polyethylene glycol derivative using these in the reaction. It is not a polyethylene glycol derivative intended to suppress cell vacuoles.

[0012] Furthermore, polyethylene glycol derivatives used to modify biological substances are generally classified into linear and branched types, and Non-Patent Document 5 describes that the branched type significantly extends the blood half-life of biological substances compared to the linear type. In recent years, most of the polyethylene glycol-modified preparations on the market have adopted the branched type. However, there have been no reports in this field so far on branched polyethylene glycol derivatives that suppress cell vacuoles.

[0013] As described above, there is a demand for branched, high molecular weight polyethylene glycol derivatives that are stable in blood, improve the blood half-life of modified biological substances, and are specifically degraded within cells when taken up into the cells, thereby suppressing the occurrence of cellular vacuoles. [Prior art documents] [Patent documents]

[0014] [Patent Document 1] Special Publication No. 2009-527581 [Patent Document 2] WO2005 / 108463 [Patent Document 3] WO2006 / 088248 [Non-patent literature]

[0015] [Non-Patent Document 1] EMA / CHMP / SWP / 647258 / 2012 [Non-Patent Document 2] Daniel G. Rudmann, et al., Toxicol. Pathol., 41, 970-983(2013) [Non-Patent Document 3] Francesco M Veronese, et al., Bioconjugate Chem., 16, 775-784(2005) [Non-Patent Document 4] Jiyuan Yang, et al., Marcomol. Biosci., 10(4), 445-454(2010) [Non-Patent Document 5] Yulia Vugmeysterang, et al., Bioconjugate Chem., 23, 1452-1462(2012) Summary of the Invention [Problem to be solved by the invention]

[0016] The object of the present invention is to provide a high molecular weight branched polyethylene glycol derivative that does not cause cellular vacuoles. More specifically, the object of the present invention is to provide a branched degradable polyethylene glycol derivative that can be effectively used for modifying biological substances, is stable in blood in a living body, and is degraded within cells, by an industrially producible method. [Means for solving the problem]

[0017] Means for Solving the Problems The present inventors conducted extensive research to solve the above problems and as a result invented a branched degradable polyethylene glycol derivative having an oligopeptide that is degraded within cells.

[0018] That is, the present invention provides a branched degradable polyethylene glycol derivative represented by the following formula (1). [1] A branched degradable polyethylene glycol derivative having an oligopeptide in the molecule that is degraded within a cell, the derivative being represented by the following formula (1):

[0019] [ka]

[0020] (In the formula, k1 and k2 each independently represent an integer from 1 to 12, j1 and j2 each independently represent an integer from 45 to 950, R represents a hydrogen atom, a substituted or unsubstituted alkyl group having 1 to 12 carbon atoms, a substituted aryl group, an aralkyl group, or a heteroalkyl group, Z represents an oligopeptide degraded by an intracellular enzyme, X represents a functional group capable of reacting with a biologically relevant substance, and L1 and L2 each independently represent a single bond or a divalent spacer.)

[0021] [2] The branched degradable polyethylene glycol derivative according to [1], wherein the degradable oligopeptide of Z is an oligopeptide having glycine as the C-terminal amino acid.

[0022] [3] The branched degradable polyethylene glycol derivative according to any one of [1] to [2], wherein the degradable oligopeptide Z is an oligopeptide having at least one hydrophobic neutral amino acid having a hydropathic index of 2.5 or more.

[0023] [4] The branched degradable polyethylene glycol derivative according to any one of [1] to [3], which has a total molecular weight of 20,000 or more.

[0024] [5] The branched degradable polyethylene glycol derivative according to any one of [1] to [4], wherein L1 and L2 each independently represent a single bond, a urethane bond, an amide bond, an ether bond, a thioether bond, a secondary amino group, a urea bond, or an alkylene group which may contain these bonds and / or groups.

[0025] [6] The branched degradable polyethylene glycol derivative according to any one of [1] to [5], wherein X is selected from the group consisting of an active ester group, an active carbonate group, an aldehyde group, an isocyanate group, an isothiocyanate group, an epoxy group, a maleimide group, a vinylsulfonyl group, an acryl group, a sulfonyloxy group, a carboxy group, a thiol group, a dithiopyridyl group, an α-haloacetyl group, an alkynyl group, an allyl group, a vinyl group, an amino group, an oxyamino group, a hydrazide group, and an azide group.

[0026] In another embodiment, the present invention provides a branched degradable polyethylene glycol derivative represented by the following formula (2): [6] A branched degradable polyethylene glycol derivative represented by the following formula (2).

[0027] [ka]

[0028] (In the formula, k1 and k2 each independently represent 1 to 12, j1 and j2 each independently represent 45 to 950, R represents a hydrogen atom, a substituted or unsubstituted alkyl group having 1 to 4 carbon atoms, a substituted aryl group, an aralkyl group or a heteroalkyl group, W represents an oligopeptide having 5 to 47 residues and a symmetric structure centered on glutamic acid or lysine, a represents 2 to 8, X represents a functional group capable of reacting with a biologically relevant substance, and L1 and L2 each independently represent a single bond or a divalent spacer.)

[0029] [7] The branched degradable polyethylene glycol derivative according to [6], wherein the symmetric oligopeptide having a center of glutamic acid or lysine as W is an oligopeptide having the following structure w1 or w2.

[0030] [ka]

[0031] [ka]

[0032] (wherein Q is a glutamic acid or lysine residue, and Z is a degradable oligopeptide of 2 to 5 residues consisting of neutral amino acids excluding cysteine.)

[0033] [8] The degradable polyethylene glycol derivative according to [7], wherein the degradable oligopeptide of Z is an oligopeptide having glycine as the C-terminal amino acid.

[0034] [9] A branched degradable polyethylene glycol derivative according to any one of [7] or [8], wherein the degradable oligopeptide of Z is an oligopeptide having at least one hydrophobic neutral amino acid having a hydropathic index of 2.5 or more.

[0035]

[10] The branched degradable polyethylene glycol derivative according to any one of [6] to [9], which has a total molecular weight of 20,000 or more.

[0036]

[11] The branched degradable polyethylene glycol derivative according to any one of [6] to

[10] , wherein L1 and L2 are each independently a single bond, a urethane bond, an amide bond, an ether bond, a thioether bond, a secondary amino group, a urea bond, or an alkylene group which may contain these bonds and / or groups.

[0037]

[12] The branched degradable polyethylene glycol derivative according to any one of [6] to

[11] , wherein X is selected from the group consisting of an active ester group, an active carbonate group, an aldehyde group, an isocyanate group, an isothiocyanate group, an epoxy group, a maleimide group, a substituted maleimide group, a vinylsulfonyl group, an acryl group, a substituted sulfonate group, a sulfonyloxy group, a carboxy group, a mercapto group, a pyridyldithio group, an α-haloacetyl group, an alkylcarbonyl group, an iodoacetamide group, an alkenyl group, an alkynyl group, a substituted alkynyl group, an amino group, an oxyamino group, a hydrazide group, and an azide group. Effect of the Invention

[0038] The branched degradable polyethylene glycol derivative of the present invention is stable in the blood of a living body and has an oligopeptide in its structure that is degraded by an enzyme in the cells. Therefore, the branched degradable polyethylene glycol derivative is stable in the blood and can impart a blood half-life equivalent to that of conventional polyethylene glycol derivatives that are not degradable to a biological substance. Furthermore, when the branched degradable polyethylene glycol derivative is taken up into a cell, the oligopeptide portion is rapidly degraded, so that the generation of cellular vacuoles, which has been a problem until now, can be suppressed. In addition, by limiting the oligopeptide introduced into the polyethylene glycol to an oligopeptide having glycine as the C-terminal amino acid, impurities generated during the manufacturing process can be reduced, and industrial manufacturing can be achieved. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0039] The present invention will be described in detail below. The branched degradable polyethylene glycol derivative according to the present invention is represented by the following formula (1).

[0040] [ka]

[0041] In formula (1), k1 and k2 each independently represent an integer from 1 to 12, j1 and j2 each independently represent an integer from 45 to 950, R represents a hydrogen atom, a substituted or unsubstituted alkyl group having 1 to 12 carbon atoms, a substituted aryl group, an aralkyl group, or a heteroalkyl group, Z represents an oligopeptide that is degraded by an intracellular enzyme, X represents a functional group capable of reacting with a biologically relevant substance, and L1 and L2 each independently represent a single bond or a divalent spacer.

[0042] The total molecular weight of the polyethylene glycol derivative of the formula (1) of the present invention is usually 4,000 to 160,000, preferably 10,000 to 120,000, and more preferably 20,000 to 80,000. In one preferred embodiment of the present invention, the total molecular weight of the polyethylene glycol derivative of the formula (1) of the present invention is 20,000 or more. The molecular weight referred to here is the number average molecular weight (Mn).

[0043] In formula (1), k1 and k2 are usually each independently 1 to 12, preferably each independently 1 to 6, and more preferably each independently 1 to 2.

[0044] In formula (1), j1 and j2 each represent the number of repeating units of polyethylene glycol, and usually each independently represents 45 to 950, preferably each independently represents 110 to 690, and more preferably each independently represents 220 to 480.

[0045] In formula (1), R is a hydrogen atom, a substituted or unsubstituted alkyl group having 1 to 12 carbon atoms, a substituted aryl group, an aralkyl group, or a heteroalkyl group. A "heteroalkyl group" is an alkyl group containing 1 to 5 heteroatoms selected from a nitrogen atom, an oxygen atom, and a sulfur atom. R is preferably a hydrogen atom or an alkyl group having 1 to 3 carbon atoms, more preferably a hydrogen atom, a methyl group, or an ethyl group, and even more preferably a hydrogen atom.

[0046] L1 and L2 in formula (1) are each independently a single bond or a divalent spacer, and there is no particular limitation on these spacers as long as they are groups capable of forming a covalent bond. However, they are preferably phenylene groups, amide bonds, ether bonds, thioether bonds, urethane bonds, secondary amino groups, carbonyl groups, urea bonds, or alkylene groups that may contain these bonds and / or groups, and more preferably alkylene groups, amide bonds, ether bonds, urethane bonds, secondary amino groups, or groups formed by bonding a carbonyl group to an alkylene group. Particularly preferred embodiments are those shown in group (I) below. Two to five spacers of group (I) may be combined. As divalent spacers, ester bonds and carbonate bonds are not suitable because they are gradually decomposed in the blood in the living body.

[0047] Group (I):

[0048] [ka]

[0049] In (z1) to (z11), s in the formulae represents an integer of 0 to 10, preferably an integer of 0 to 6, and more preferably an integer of 0 to 3. In (z2) to (z11), s in the formulae may be the same or different.

[0050] L1 in formula (1) is preferably a single bond or (z2), (z3), (z4), (z6), (z7), (z8), (z9), (z10), or a combination of (z2) and (z6) in group (I), and more preferably a single bond, or a combination of (z3), (z6), (z9), (z10), or (z2) and (z6). L2 in formula (1) is preferably (z1), (z2), (z3), (z4), (z5), (z6), (z7), (z8) or (z11) in group (I), and more preferably (z3), (z5) or (z11).

[0051] Z in formula (1) is not particularly limited as long as it is an oligopeptide that is stable in blood in the living body and is decomposed by intracellular enzymes, but is preferably an oligopeptide of 2 to 8 residues composed of neutral amino acids excluding cysteine, more preferably an oligopeptide of 2 to 6 residues composed of neutral amino acids excluding cysteine, and even more preferably an oligopeptide of 2 to 4 residues composed of neutral amino acids excluding cysteine.

[0052] In addition, Z in formula (1) is preferably an oligopeptide composed of an amino acid having an amino group or a carboxyl group in the side chain, specifically, a neutral amino acid not including lysine, aspartic acid, or glutamic acid. The amino acid used here is an α-amino acid, and is basically an L-type amino acid.

[0053] Furthermore, since cysteine, which is a neutral amino acid, has a thiol group and forms a disulfide bond with another thiol group, Z in formula (1) is preferably an oligopeptide composed of neutral amino acids that do not contain cysteine.

[0054] In addition, Z in formula (1) is preferably an oligopeptide having glycine as the C-terminal amino acid. When reacting the C-terminal carboxyl group with a polyethylene glycol derivative, it is basically necessary to activate the C-terminal carboxyl group with a condensing agent or the like. It is known that epimerization is likely to occur with amino acids other than glycine during this activation process, resulting in the by-production of stereoisomers. By using achiral glycine as the C-terminal amino acid of the oligopeptide, a highly pure target product can be obtained without the by-production of stereoisomers.

[0055] Furthermore, Z in formula (1) is preferably a hydrophobic neutral amino acid having a hydropathic index of 2.5 or more, specifically, an oligopeptide having at least one of phenylalanine, leucine, valine, and isoleucine, and more preferably an oligopeptide having phenylalanine. The hydropathy index, which was created by Kyte and Doolittle to quantitatively indicate the hydrophobicity of amino acids, indicates that the higher the value, the more hydrophobic the amino acid is (Kyte J & Doolittle RF, 1982, J Mol Biol, 157:105-132.).

[0056] Z in formula (1) is not particularly limited as long as it is stable in the blood of a living body, has the ability to be decomposed by an intracellular enzyme, and is an oligopeptide of 2 to 8 residues consisting of neutral amino acids other than cysteine. Specific examples include glycine-phenylalanine-leucine-glycine, glycine-glycine-phenylalanine-glycine, glycine-phenylalanine-glycine, glycine-leucine-glycine, valine-citrulline-glycine, valine-alanine-glycine, glycine-glycine-glycine, phenylalanine-glycine, etc., and preferably glycine-phenylalanine. Preferred are glycine-phenylalanine-leucine-glycine, glycine-glycine-phenylalanine-glycine, glycine-phenylalanine-glycine, glycine-glycine-glycine, valine-citrulline-glycine, valine-alanine-glycine, and phenylalanine-glycine, more preferably glycine-phenylalanine-leucine-glycine, glycine-phenylalanine-glycine, valine-citrulline-glycine, and valine-alanine-glycine, and even more preferably glycine-phenylalanine-leucine-glycine and valine-citrulline-glycine.

[0057] X in formula (1) is not particularly limited as long as it is a functional group that reacts with a functional group present in a biologically relevant substance such as a physiologically active protein, peptide, antibody, or nucleic acid to be chemically modified to form a covalent bond. For example, functional groups described in "Harris, JM Poly(Ethylene Glycol) Chemistry; Plenum Press: New York, 1992", "Hermanson, GT Bioconjugate Techniques, 2nd ed.; Academic Press: San Diego, CA, 2008" and "PEGylated Protein Drugs: Basic Science and Clinical Applications; Veronese, FM, Ed.; Birkhauser: Basel, Switzerland, 2009" can be mentioned.

[0058] The "functional group capable of reacting with a bio-relevant substance" represented by X in formula (1) is not particularly limited as long as it is a functional group capable of chemically bonding with a functional group, such as an amino group, a mercapto group, an aldehyde group, a carboxy group, an unsaturated bond, or an azide group, possessed by the bio-relevant substance. Specific examples of the group include an active ester group, an active carbonate group, an aldehyde group, an isocyanate group, an isothiocyanate group, an epoxy group, a carboxy group, a mercapto group, a maleimide group, a substituted maleimide group, a hydrazide group, a dithiopyridyl group, a substituted sulfonate group, a vinylsulfonyl group, an amino group, an oxyamino group (HN-O- group), an iodoacetamide group, an alkylcarbonyl group, an alkenyl group (e.g., an allyl group, a vinyl group), an alkynyl group, a substituted alkynyl group (e.g., an alkynyl group substituted with a hydrocarbon group having 1 to 5 carbon atoms, as described below), an azide group, an acryl group, a sulfonyloxy group (e.g., an alkylsulfonyloxy group), and an α-haloacetyl group. Preferred are an active ester group, an active carbonate group, an aldehyde group, and an isocyanate group. , isothiocyanate group, epoxy group, maleimide group, substituted maleimide group, vinylsulfonyl group, acryl group, sulfonyloxy group (for example, alkyl-sulfonyloxy group having 1 to 5 carbon atoms), substituted sulfonate group, carboxy group, mercapto group, pyridyldithio group, α-haloacetyl group, alkynyl group, substituted alkynyl group (for example, alkynyl group having 2 to 5 carbon atoms substituted with a hydrocarbon group having 1 to 5 carbon atoms described later), allyl group, vinyl group, amino group, oxyamino group, hydrazide group and azide group are more preferred, active ester group, active carbonate group, aldehyde group, maleimide group, oxyamino group and amino group are particularly preferred, active ester group, active carbonate group, aldehyde group, maleimide group and oxyamino group.

[0059] In another preferred embodiment, the functional group X can be classified into the following groups (II), (III), (IV), (V), (VI) and (VII).

[0060] Group (II): Functional groups capable of reacting with amino groups in biologically relevant substances Examples of the groups include those represented by the following (a), (b), (c), (d), (e), (f), (g), (j) and (k).

[0061] Group (III): Functional groups capable of reacting with mercapto groups in biologically relevant substances Examples of the groups include those represented by the following (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), and (l).

[0062] Group (IV): Functional groups capable of reacting with aldehyde groups in biologically relevant substances Examples of the groups include those represented by the following (h), (m), (n) and (p).

[0063] Group (V): Functional groups capable of reacting with carboxyl groups of biologically relevant substances Examples of the groups include those represented by the following (h), (m), (n) and (p).

[0064] Group (VI): Functional groups capable of reacting with unsaturated bonds in biologically relevant substances Examples of the groups include those represented by the following (h), (m), and (o).

[0065] Group (VII): Functional groups capable of reacting with azide groups in biologically relevant substances Examples include the group represented by (l) below.

[0066] [ka]

[0067] In the functional group (j), W1 in the formula represents a halogen atom such as a chlorine atom (Cl), a bromine atom (Br) or an iodine atom (I), and is preferably Br or I, and more preferably I.

[0068] In addition, in the functional group (e) and the functional group (l), Y 1 , Y 3 each independently represents a hydrogen atom or a hydrocarbon group having 1 to 5 carbon atoms, preferably a hydrocarbon group having 1 to 5 carbon atoms. Specific examples of the hydrocarbon group having 1 to 5 carbon atoms include a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, and a tertiary butyl group, and preferably a methyl group or an ethyl group.

[0069] In addition, in the functional group (k), Y in the formula 2 represents a hydrocarbon group having 1 to 10 carbon atoms which may contain a fluorine atom, and specific examples thereof include a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, a tert-butyl group, a hexyl group, a nonyl group, a vinyl group, a phenyl group, a benzyl group, a 4-methylphenyl group, a trifluoromethyl group, a 2,2,2-trifluoroethyl group, and a 4-(trifluoromethoxy)phenyl group, and is preferably a methyl group, a vinyl group, a 4-methylphenyl group, or a 2,2,2-trifluoroethyl group.

[0070] The active ester group is an ester group having an alkoxy group with high leaving ability. Examples of the alkoxy group with high leaving ability include alkoxy groups derived from nitrophenol, N-hydroxysuccinimide, pentafluorophenol, etc. The active ester group is preferably an ester group having an alkoxy group derived from N-hydroxysuccinimide.

[0071] The active carbonate group is a carbonate group having an alkoxy group with high leaving ability. Examples of the alkoxy group with high leaving ability include alkoxy groups derived from nitrophenol, N-hydroxysuccinimide, pentafluorophenol, etc. The active carbonate group is preferably a carbonate group having an alkoxy group derived from nitrophenol or N-hydroxysuccinimide.

[0072] The substituted maleimide group is a maleimide group having a hydrocarbon group bonded to one of the carbon atoms of the double bond of the maleimide group. Specific examples of the hydrocarbon group include a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, and a tertiary butyl group, and preferably a methyl group or an ethyl group.

[0073] The substituted sulfonate group is a sulfonate group in which a hydrocarbon group that may contain a fluorine atom is bonded to the sulfur atom of the sulfonate group.Specific examples of the hydrocarbon group that may contain a fluorine atom include a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, a tertiary butyl group, a hexyl group, a nonyl group, a vinyl group, a phenyl group, a benzyl group, a 4-methylphenyl group, a trifluoromethyl group, a 2,2,2-trifluoroethyl group, and a 4-(trifluoromethoxy)phenyl group, and preferably a methyl group, a vinyl group, a 4-methylphenyl group, or a 2,2,2-trifluoroethyl group.

[0074] Suitable examples of the branched degradable polyethylene glycol derivative of the formula (1) of the present invention include the following branched degradable polyethylene glycol derivatives. [Branched degradable polyethylene glycol derivative (1-1)] k1 and k2 are each independently 1 to 2; j1 and j2 are each independently 220 to 480; R is a hydrogen atom; Z is an oligopeptide of 2 to 8 residues consisting of neutral amino acids excluding cysteine ​​(e.g., phenylalanine-glycine); X is selected from the group consisting of an active ester group (e.g., an N-succinimidyloxycarbonyl group), an aldehyde group (e.g., an N-(formylethyl)carbamoyl group), a carboxyl group, a maleimide group (e.g., an N-(N-maleimidylethylcarbonylaminoethyl)carbamoyl group) and an amino group (e.g., an N-(aminoethyl)carbamoyl group); L1 and L2 are each independently an alkylene group (e.g., a propylene group) which may contain a secondary amino group and / or a carbonyl group; A branched degradable polyethylene glycol derivative of formula (1).

[0075] The branched degradable polyethylene glycol derivative represented by formula (1) can be produced, for example, by the following steps.

[0076] Reaction 1

[0077] [ka]

[0078] In reaction 1, A is a leaving group, and R, j1, k1, and k2 are as defined above.

[0079] In formula (3), A is a leaving group. There are no particular limitations on the leaving group as long as it is reactive in a coupling reaction. Examples of the leaving group include a chloro group, a bromo group, an iodo group, a mesylate group, a tosylate group, and a chloromethanesulfonate group.

[0080] Reaction 1 is a step in which a polyethylene glycol derivative represented by formula (3) and a compound represented by formula (4) are subjected to a coupling reaction in an anhydrous solvent in the presence of a strong base catalyst to obtain a polyethylene glycol derivative represented by formula (5).

[0081] The strong base catalyst in the coupling reaction is not particularly limited as long as it is a strong base catalyst that allows the reaction to proceed, and examples thereof include potassium hydroxide, sodium hydroxide, sodium methoxide, and sodium ethoxide. The anhydrous solvent in the coupling reaction is not particularly limited as long as it is a solvent that does not react with the compounds represented by formula (3) and formula (4). Examples of the anhydrous solvent include aprotic polar solvents such as tetrahydrofuran, acetonitrile, DMF, dichloromethane, and chloroform, and mixtures thereof. It is preferable to purify and remove impurities produced as by-products in the reaction, compounds remaining in the reaction without being consumed, and the strong base catalyst. The purification method is not particularly limited, and can be extraction, recrystallization, adsorption treatment, reprecipitation, column chromatography, supercritical extraction, or the like.

[0082] Reaction 2

[0083] [ka]

[0084] In reaction 2, Pro is a protecting group, Peptide is an oligopeptide, L3 is a single bond or a divalent spacer having the same meaning as L1 and L2 above, and j2 is the same meaning as above.

[0085] Pro in reaction 2 is a protecting group, where a protecting group is a moiety that prevents or blocks the reaction of a particular chemically reactive functional group in a molecule under certain reaction conditions. Protecting groups vary depending on the type of chemically reactive functional group being protected, the conditions used, and the presence of other functional groups or protecting groups in the molecule. Specific examples of protecting groups can be found in many general textbooks, for example, "Wuts, PGM; Greene, TW Protective Groups in Organic Synthesis, 4th ed.; Wiley-Interscience: New York, 2007". In addition, functional groups protected with protecting groups can be deprotected, i.e., chemically reacted, using reaction conditions appropriate for each protecting group to regenerate the original functional group. Representative deprotection conditions for protecting groups are described in the above-mentioned literature.

[0086] Reaction 2 is a process in which a carboxyl group of an oligopeptide having an N-terminal amino group protected with a protecting group, represented by formula (6), is bonded by a condensation reaction to an amino group of a polyethylene glycol derivative having a methoxy group at one end, represented by formula (7), to obtain a polyethylene glycol derivative represented by formula (8).

[0087] The protecting group for the N-terminal amino group of the oligopeptide is not particularly limited, and examples thereof include acyl-based protecting groups and carbamate-based protecting groups, specifically, trifluoroacetyl group, 9-fluorenylmethyloxycarbonyl group (Fmoc), tert-butyloxycarbonyl group, etc.

[0088] The condensation reaction is not particularly limited, but a reaction using a condensing agent is preferable. As the condensing agent, a carbodiimide-based condensing agent such as dicyclohexylcarbodiimide (DCC) or 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) may be used alone, or may be used in combination with a reagent such as N-hydroxysuccinimide (NHS), 1-hydroxybenzotriazole (HOBt), or 1-hydroxy-7-azabenzotriazole (HOAt). In addition, a more reactive condensing agent such as HATU, HBTU, TATU, TBTU, COMU, or 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride n-hydrate (DMT-MM) may be used. In order to promote the reaction, a base such as triethylamine or dimethylaminopyridine may be used.

[0089] It is preferable to remove impurities produced as by-products in the reaction, or oligopeptides and condensing agents remaining unconsumed in the reaction, by purification, which is not particularly limited, and can be performed by extraction, recrystallization, adsorption treatment, reprecipitation, column chromatography, supercritical extraction, or the like.

[0090] Deprotection 3

[0091] [ka]

[0092] Peptide, L3 and j2 are as defined above.

[0093] Deprotection 3 is a step of deprotecting the protecting group of the polyethylene glycol derivative represented by formula (8) obtained in reaction 2 to obtain a polyethylene glycol derivative represented by formula (9). A conventionally known method can be used for the deprotection reaction, but it is necessary to use conditions under which the oligopeptide or the divalent spacer of L3 is not decomposed. This step can also be carried out as a part of reaction 2.

[0094] It is preferable to remove impurities generated as by-products in the deprotection reaction by purification, which is not particularly limited, and can be performed by extraction, recrystallization, adsorption treatment, reprecipitation, column chromatography, supercritical extraction, or the like.

[0095] Reaction 4

[0096] [ka]

[0097] In Reaction 4, k3 is an integer of 1 to 6, and Peptide, j2, and L3 are as defined above.

[0098] In the formula (8), k3 is an integer of 1 to 6, and preferably an integer of 2 to 4.

[0099] Reaction 4 is a step in which the terminal amino group of the polyethylene glycol derivative represented by formula (9) obtained in deprotection 3 is reacted with a compound represented by formula (10) in the presence of a base catalyst to convert it into a carboxyl group.

[0100] It is preferable to remove impurities and the like produced as by-products in reaction 4 by purification. The purification method is not particularly limited, but can be performed by extraction, recrystallization, adsorption treatment, reprecipitation, column chromatography, supercritical extraction, or the like.

[0101] Reaction 5

[0102] [ka]

[0103] In Reaction 5, Peptide, L3, k3, and j2 are as defined above.

[0104] Reaction 5 is a step in which the polyethylene glycol derivative represented by formula (11) obtained in reaction 4 is reacted with a compound represented by formula (12) in the presence of a base catalyst to obtain a polyethylene glycol derivative represented by formula (13) having an active ester group introduced therein, and this step can also be carried out as a part of reaction 4.

[0105] Reaction 6

[0106] [ka]

[0107] In Reaction 6, Peptide, R, L3, j1, j2, k1, k2, and k3 are as defined above.

[0108] Reaction 6 is a step in which the amino group of the polyethylene glycol derivative represented by formula (5) obtained in reaction 1 is bonded to the active ester group of the polyethylene glycol derivative represented by formula (13) obtained in reaction 5, to obtain a branched degradable polyethylene glycol derivative represented by formula (14).

[0109] It is preferable to remove impurities produced as by-products in the reaction, or polyethylene glycol derivatives remaining unconsumed in the reaction, by purification. The purification method is not particularly limited, and can be performed by extraction, recrystallization, adsorption treatment, reprecipitation, column chromatography, supercritical extraction, or the like.

[0110] A typical example of the step of converting the terminal carboxyl group of the polyethylene glycol derivative represented by formula (14) into another functional group will be described below, but the conversion method is not limited thereto.

[0111] For example, when it is desired to convert the terminal carboxyl group of the polyethylene glycol derivative represented by formula (15) into a maleimide group, the target compound can be obtained by a condensation reaction with N-(2-aminoethyl)maleimide in the presence of a base catalyst.

[0112] For example, when it is desired to convert the terminal carboxyl group of the polyethylene glycol derivative represented by formula (14) to an amino group, it is possible to obtain the compound by carrying out a condensation reaction with N-(9-H-fluoren-9-ylmethoxycarbonyl)-1,2-ethanediamine in the presence of a base catalyst, followed by a deprotection reaction.

[0113] These reaction reagents are low molecular weight reagents and have a significantly different solubility from polyethylene glycol derivatives, which are high molecular weight polymers, and therefore can be easily removed by common purification methods such as extraction and crystallization.

[0114] In still another embodiment of the present invention, there is provided a branched degradable polyethylene glycol derivative represented by the following formula (2):

[0115] [ka]

[0116] In formula (2), k1 and k2 each independently represent an integer from 1 to 12, j1 and j2 each independently represent an integer from 45 to 950, R represents a hydrogen atom, a substituted or unsubstituted alkyl group having 1 to 4 carbon atoms, a substituted aryl group, an aralkyl group or a heteroalkyl group, W represents an oligopeptide having 5 to 47 residues and a symmetrical structure centered on glutamic acid or lysine, a represents an integer from 2 to 8, X represents a functional group capable of reacting with a biologically relevant substance, and L1 and L2 each independently represent a single bond or a divalent spacer.

[0117] The total molecular weight of the polyethylene glycol derivative of the formula (2) of the present invention is usually 4,000 to 160,000, preferably 10,000 to 120,000, and more preferably 20,000 to 80,000. In one preferred embodiment of the present invention, the total molecular weight of the polyethylene glycol derivative of the formula (2) of the present invention is 20,000 or more. The molecular weight here refers to the number average molecular weight (Mn).

[0118] In formula (2), k1 and k2 are usually each independently 1 to 12, preferably each independently 1 to 6, and more preferably each independently 1 to 2.

[0119] In formula (2), j1 and j2 each represent the number of repeating units of polyethylene glycol, and usually each independently represents 45 to 950, preferably each independently represents 110 to 690, and more preferably each independently represents 220 to 480.

[0120] W in formula (2) is an oligopeptide of 5 to 47 residues, preferably 5 to 27 residues, more preferably 5 to 19 residues, with glutamic acid or lysine as the center, and is stable in the blood of the living body and decomposed by intracellular enzymes. However, the amino acids constituting the oligopeptide are preferably composed of neutral amino acids other than cysteine, except for glutamic acid or lysine constituting the central part. The symmetrical oligopeptide with glutamic acid or lysine as the center means a compound in which the same peptide is bound to the α-position carboxyl group and the γ-position carboxyl group of glutamic acid or the α-position amino group and the ε-position amino group of lysine, and is an oligopeptide in which the paired peptides have a symmetrical structure with glutamic acid or lysine as the center. The ratio of the number of neutral amino acids and glutamic acids or lysines in the oligopeptide (number of neutral amino acids / number of glutamic acids) is usually 2 to 10, preferably 2 to 8, and more preferably 2 to 6. The amino acids constituting W are basically L-type.

[0121] Particularly preferred embodiments of W are those shown in group (VIII) below. Group (VIII):

[0122] [ka]

[0123] [ka]

[0124] (In the formula, Q is a glutamic acid or lysine residue, and Z is a degradable oligopeptide of 2 to 5 residues consisting of neutral amino acids excluding cysteine.)

[0125] In formula (2), a is the number of polyethylene glycol chains bonded to the oligopeptide represented by W, and is usually 2 to 8, preferably 2, 4 or 8, and more preferably 2 or 4.

[0126] The preferred embodiments of R, X, L1, L2 and Z in (w1) and (w2) are as explained for the formula (1).

[0127] One of the preferred embodiments of the formula (2) is a three-branched degradable polyethylene glycol derivative represented by the following formula (15), in which W is w1 and a=2.

[0128] [ka]

[0129] (In the formula, Q, Z, R, k1, k2, j1, j2, X, L1 and L2 are as defined above.)

[0130] One of the preferred embodiments of formula (2) is a 5-branched degradable polyethylene glycol derivative represented by the following formula (16), in which W is w2 and a=4.

[0131] [ka]

[0132] (In the formula, Q, R, Z, k1, k2, j1, j2, X, L1 and L2 are as defined above.)

[0133] Suitable examples of the branched degradable polyethylene glycol derivative of the formula (2) of the present invention include the following branched degradable polyethylene glycol derivatives. [Branched degradable polyethylene glycol derivative (2-1)] k1 and k2 are each independently 1 to 2; j1 and j2 are each independently 220 to 480; R is a hydrogen atom; W is a symmetric oligopeptide of 5-9 residues centered on glutamic acid or lysine (e.g., glycine-phenylalanine-glutamic acid-phenylalanine-glycine); a is 2 or 4; X is a carboxyl group; L1 and L2 each independently represent an alkylene group (e.g., a propylene group, a pentylene group) which may contain an ether bond, a secondary amino group, and / or a carbonyl group; A branched degradable polyethylene glycol derivative of formula (2).

[0134] The branched degradable polyethylene glycol derivative of the present invention, in which Q is a glutamic acid residue, can be produced, for example, by the following steps.

[0135] Reaction 7

[0136] [ka]

[0137] In Reaction 7, Pro, Peptide, L3 and j2 are as defined above.

[0138] Reaction 7 is a process in which the amino group of the polyethylene glycol derivative represented by formula (9) obtained in deprotection 3 is bonded by a condensation reaction to two carboxyl groups of a glutamic acid derivative represented by formula (17) in which the amino group is protected with a protecting group, to obtain a branched polyethylene glycol derivative represented by formula (18) in which two degradable polyethylene glycol chains are linked by a glutamic acid residue. As in the above reaction 2, the reaction is preferably carried out using a condensing agent, and a base such as triethylamine or dimethylaminopyridine may be used to promote the reaction. The protecting group for the amino group of glutamic acid is not particularly limited, and examples thereof include acyl-based protecting groups and carbamate-based protecting groups, and specific examples thereof include a trifluoroacetyl group, a 9-fluorenylmethyloxycarbonyl group, and a t-butyloxycarbonyl group. It is preferable to remove impurities produced as by-products in the reaction, or polyethylene glycol derivatives remaining unconsumed in the reaction, by purification. The purification method is not particularly limited, and can be extraction, recrystallization, adsorption treatment, reprecipitation, column chromatography, supercritical extraction, or the like.

[0139] Deprotection 8

[0140] [ka]

[0141] In the deprotection 8, Peptide, L3 and j2 are as defined above.

[0142] Deprotection 8 is a step of deprotecting the protecting group of the polyethylene glycol derivative represented by formula (18) obtained in reaction 7 to obtain a polyethylene glycol derivative represented by formula (19). The reaction and purification can be carried out under the same conditions as in deprotection 3. As a method for removing polyethylene glycol impurities having different molecular weights or functional groups from the polyethylene glycol derivative represented by formula (19), the purification techniques described in JP-A-2014-208786 and JP-A-2011-79934 can be used.

[0143] Reaction 9

[0144] [ka]

[0145] In Reaction 9, Pro, Peptide, L3 and j2 are as defined above.

[0146] Reaction 9 is a process in which the amino group of the polyethylene glycol derivative represented by formula (19) obtained in deprotection 8 is bonded by a condensation reaction with two carboxyl groups of a glutamic acid derivative represented by formula (17) in which the amino group is protected with a protecting group, to obtain a branched polyethylene glycol derivative represented by formula (20) in which four degradable polyethylene glycol chains are linked by glutamic acid residues. The reaction and purification can be carried out under the same conditions as in Reaction 2.

[0147] Deprotection 10

[0148] [ka]

[0149] In the deprotected 10, Peptide, L3 and j2 are as defined above.

[0150] Deprotection 10 is a step of deprotecting the protecting group of the polyethylene glycol derivative represented by formula (20) obtained in reaction 9 to obtain a polyethylene glycol derivative represented by formula (21). The reaction and purification can be carried out under the same conditions as in the deprotection 8. This step can also be carried out in a series of steps in reaction 9.

[0151] Reaction 11

[0152] [ka]

[0153] In reaction 11, Peptide, L3, j2 and k3 are as defined above.

[0154] Reaction 11 is a process in which the terminal amino group of the bibranched polyethylene glycol derivative represented by formula (19) obtained in deprotection 8 is reacted with a compound represented by formula (22) in the presence of a base catalyst to convert it to a hydroxyl group, thereby obtaining a bibranched polyethylene glycol derivative represented by formula (23). The reaction and purification can be carried out under the same conditions as in Reaction 4.

[0155] Furthermore, by using the 4-branched polyethylene glycol derivative represented by formula (21) obtained in deprotection 10 as a raw material instead of the 2-branched polyethylene glycol derivative represented by formula (19) in reaction 11, a 4-branched polyethylene glycol derivative represented by formula (24) below can be obtained.

[0156] [ka]

[0157] Peptide, L3, j2 and k3 in formula (24) are as defined above.

[0158] Reaction 12

[0159] [ka]

[0160] In reaction 12, Peptide, L3, j2 and k3 are as defined above.

[0161] Reaction 12 is a process in which the hydroxyl group of the bibranched polyethylene glycol derivative represented by formula (23) obtained in reaction 11 is reacted with a compound represented by formula (25) to obtain a bibranched polyethylene glycol derivative represented by formula (26) having an active carbonate group introduced therein. This process can also be carried out as a part of the subsequent process of reaction 11, and the reaction and purification can be carried out under the same conditions as those for reaction 5.

[0162] Furthermore, by using a 4-branched polyethylene glycol derivative represented by formula (24) as a raw material instead of the 2-branched polyethylene glycol derivative represented by formula (23) in reaction 12, a 4-branched polyethylene glycol derivative represented by formula (27) below can be obtained.

[0163] [ka]

[0164] Peptide, L3, j2 and k3 in formula (27) are as defined above.

[0165] Reaction 13

[0166] [ka]

[0167] In reaction 13, Peptide, R, L3, j1, j2, k1, k2 and k3 are as defined above.

[0168] Reaction 13 is a step in which the amino group of the polyethylene glycol derivative represented by formula (5) obtained in reaction 1 is bonded to the active ester group of the polyethylene glycol derivative represented by formula (26) obtained in reaction 12 to obtain a three-branched degradable polyethylene glycol derivative represented by formula (28). The reaction and purification can be carried out under the same conditions as in reaction 6.

[0169] Furthermore, by using a 4-branched polyethylene glycol derivative represented by formula (27) as a raw material instead of the 2-branched polyethylene glycol derivative represented by formula (26) in reaction 13, a 5-branched polyethylene glycol derivative represented by the following formula (29) can be obtained.

[0170] [ka]

[0171] Peptide, R, L3, j1, j2, k1, k2 and k3 in formula (29) are as defined above.

[0172] Regarding the step of converting the terminal carboxyl group of the branched polyethylene glycol derivative represented by formula (28) or formula (29) into another functional group, a typical example will be described below, but the conversion method is not limited thereto.

[0173] For example, when the terminal carboxyl group of the branched polyethylene glycol derivative represented by formula (28) or formula (29) is to be converted into a maleimide group, the target compound can be obtained by condensation reaction with N-(2-aminoethyl)maleimide in the presence of a base catalyst.

[0174] For example, when it is desired to convert the terminal carboxyl group of the polyethylene glycol derivative represented by formula (28) or formula (29) into an amino group, it can be obtained by carrying out a condensation reaction with N-(9-H-fluoren-9-ylmethoxycarbonyl)-1,2-ethanediamine in the presence of a base catalyst, followed by a deprotection reaction.

[0175] These reaction reagents are low molecular weight reagents and have a significantly different solubility from polyethylene glycol derivatives, which are high molecular weight polymers, and therefore can be easily removed by common purification methods such as extraction and crystallization.

[0176] The branched degradable polyethylene glycol obtained through the above-mentioned processes is required to have the ability to be stable in blood and degrade only within cells. In order to appropriately evaluate the performance, for example, the following tests can be performed to evaluate the stability of the branched degradable polyethylene glycol in blood and its degradability within cells. In addition, in consideration of the influence of the type of functional group possessed by the polyethylene glycol derivative in these evaluations, all evaluation samples were standardized to polyethylene glycol derivatives having one amino group and the tests were carried out.

[0177] There is no particular limitation on the test method for evaluating the stability of the branched degradable polyethylene glycol derivative in blood, and examples thereof include tests using serum from mice, rats, humans, etc. Specifically, the polyethylene glycol derivative is dissolved in serum to a concentration of 1 to 10 mg / mL, incubated at 37°C for 96 hours, and the polyethylene glycol derivative contained in the serum is collected and subjected to GPC measurement to evaluate the decomposition rate. The decomposition rate is calculated from the peak area % of the GPC main fraction of the polyethylene glycol derivative before the stability test and the peak area % of the GPC main fraction of the polyethylene glycol derivative after the stability test. Specifically, the following formula is used. Decomposition rate = (Peak area% before test - Peak area% after test) ÷ Peak area% before test × 100 For example, if the peak area % of the GPC main fraction of a branched degradable polyethylene glycol derivative before the stability test is 95% and the peak area % of the GPC main fraction after the test is 90%, the decomposition rate is calculated as follows. Decomposition rate = (95-90)÷95×100 = 5.26(%) If a branched degradable polyethylene glycol derivative is degraded in blood, the desired half-life in blood cannot be obtained. Therefore, in a stability test, the decomposition rate after 96 hours is preferably 10% or less, and more preferably 5% or less.

[0178] There is no particular limitation on the test method for evaluating the degradability of the branched degradable polyethylene glycol derivative in cells, and examples thereof include a test in which cells are cultured using a medium containing the branched degradable polyethylene glycol derivative. There is no particular limitation on the cells and medium used here, but specifically, the polyethylene glycol derivative is dissolved in RPMI-1640 medium to a concentration of 1 to 20 mg / mL, and macrophage cells RAW264.7 are cultured using this medium at 37°C for 96 hours, after which the polyethylene glycol derivative in the cells is recovered and the degradation rate is evaluated by measuring GPC. The degradation rate is calculated using the peak area % of the GPC main fraction of the polyethylene glycol derivative before and after the test, as in the stability test. For example, if the peak area % of the GPC main fraction of a branched degradable polyethylene glycol derivative before the cell-based degradation test is 95% and the peak area % of the GPC main fraction after the test is 5%, the degradation rate is calculated as follows. Decomposition rate = (95-5)÷95×100 = 94.7(%) Unless the branched degradable polyethylene glycol derivative is efficiently degraded within the cells, it cannot suppress vacuoles in the target cells. Therefore, in a degradability test, the decomposition rate after 96 hours is preferably 90% or more, and more preferably 95% or more.

[0179] Non-Patent Document 2 describes that cellular vacuolation caused by high molecular weight polyethylene glycol is related to the accumulation of polyethylene glycol in tissues. There are no particular limitations on the test method for evaluating the cellular accumulation of degradable polyethylene glycol derivatives, but the above-mentioned intracellular degradability can be used to evaluate the accumulation. EXAMPLES

[0180] The present invention will be described in more detail below with reference to examples, but the present invention is not limited to the following examples.

[0181] Obtained in the following examples 1H-NMR was obtained from JNM-ECP400 or JNM-ECA600 manufactured by JEOL Datum Co., Ltd. A φ5 mm tube was used for the measurement, and D2O or CDCl3 and d6-DMSO containing tetramethylsilane (TMS) as an internal standard were used as deuterated solvents. The molecular weight and terminal functional group purity of the obtained polyethylene glycol derivatives were calculated using liquid chromatography (GPC and HPLC). The liquid chromatography systems used for GPC were "HLC-8320GPC EcoSEC" manufactured by Tosoh Corporation, and for HPLC, "ALLIANCE" manufactured by WATERS was used.

[0182] [Example 1]

[0183] [ka]

[0184] [Example 1-1]

[0185] [ka]

[0186] Average molecular weight = 20,000, NOF Corporation "SUNBRIGHT MEH-20T" (10g) was dissolved in toluene (40g), refluxed at 110 ° C for 1 hour, cooled to 40 ° C, triethylamine (80mg) and methanesulfonyl chloride (84mg) were added, and reacted at 40 ° C for 3 hours. After the reaction was completed, it was diluted with toluene (100g), hexane (100g) was added, and the mixture was stirred at room temperature for 30 minutes to precipitate the product. After suction filtration using 5A filter paper and collecting the precipitate, it was dissolved in ethyl acetate (200g), hexane (100g) was added, and the mixture was stirred at room temperature for 15 minutes to precipitate the product. After suction filtration using 5A filter paper and collecting the precipitate, it was washed with hexane (100g), suction filtration using 5A filter paper, and vacuum dried to obtain compound (p1). Yield 8.9g. 1 H-NMR(CDCl3):3.08ppm(s, 3H, -O-SO2-CH 3)3.38ppm(s, 3H, -O-CH2-CH2-(O-CH2-CH2) j -O- CH 3), 3.64ppm(m, approx. 1,900H, -O-CH2-CH2-(O- CH 2 -CH 2) j -O-CH3)

[0187] [Example 1-2]

[0188] [ka]

[0189] Glycine hydrochloride (5 g) was dissolved in ion-exchanged water (50 g). NaOH (3.0 g) was added to the glycine aqueous solution to adjust the pH to 10.8. Then, compound (p1) (8 g) obtained in Example 1-1 was added to the aqueous solution, and the solution was reacted at 40° C. for 72 hours. After the reaction, the pH of the reaction solution was neutralized to about 7 with a hydrochloric acid solution. After neutralization, chloroform (50 g) was added, and the solution was stirred at room temperature for 15 minutes, and the organic layer was collected. The organic layer was concentrated, redissolved in ethyl acetate (100 g), and hexane (50 g) was added, and the solution was stirred at room temperature for 15 minutes to precipitate the product. The precipitate was collected by suction filtration using 5A filter paper, washed with hexane (50 g), suction filtration using 5A filter paper, and vacuum dried to obtain compound (p2). Yield 6.8 g. 1 H-NMR(d6-DMSO):2.72ppm(t, 2H, -NH- CH 2-CH2-(O-CH2-CH2) j -O-CH3)3.24ppm(s, 3H, -NH-CH2-CH2-(O-CH2-CH2) j -O- CH 3), 3.48ppm(m, approx. 1,900H, - CH 2-NH-CH2- CH 2-(O- CH 2 -CH 2) j -O-CH3), 5.52ppm(broad, 1H, - NH -CH2-COOH)

[0190] [Examples 1-3]

[0191] [ka]

[0192] L-phenylalanyl-glycine (Fmoc-Phe-Gly) (0.44 g) with the N-terminus protected by a 9-fluorenylmethyloxycarbonyl group (Fmoc group) and NOF Corp.'s "SUNBRIGHT MEPA-20T" (10 g) with an average molecular weight of 20,000 were dissolved in acetonitrile (40 g). Then, diisopropylethylamine (1.56 g) and 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride n-hydrate (DMT-MM) (0.22 g) were added and reacted at room temperature under a nitrogen atmosphere for 1 hour. After the reaction was completed, the mixture was concentrated at 40°C, toluene (100 g) was added to the concentrate and stirred to make it uniform, and then suction filtered using 5A filter paper. Hexane (100 g) was added to the obtained filtrate, and the product was precipitated by stirring at room temperature for 15 minutes. The precipitate was collected by suction filtration using 5A filter paper, and then dissolved again in toluene (100 g), and hexane (100 g) was added and stirred at room temperature for 15 minutes to precipitate the product. The precipitate was collected by suction filtration using 5A filter paper, and then washed with hexane (50 g), suction filtration using 5A filter paper, and vacuum dried to obtain the above compound (p3). Yield: 8.6 g. 1 H-NMR(d6-DMSO): 1.62ppm(m, 2H, -CO-NH-CH2- CH 2-CH2-O-(CH2-CH2-O)j-CH3), 2.80ppm(m, 1H, -NH-CO-CH- CH 2-C6H5), 3.04ppm(m, 1H, -NH-CO-CH- CH 2-C6H5), 3.10ppm(m, 2H, -CO-NH- CH 2-CH2-CH2-O-(CH2-CH2-O)j-CH3), 3.24ppm(s, 3H, -CO-NH-CH2-CH2-CH2-O-(CH2-CH2-O)j- CH3), 3.48ppm(m, approx. 1,900H, -CO-NH-CH2-CH2-CH2-O-( CH 2 -CH 2-O)j-CH3), 4.20ppm(m, 4H), 7.33ppm(m, 9H), 7.66ppm(m, 4H, Ar), 7.88ppm(d, 2H, Ar), 8.27ppm(t, 1H)

[0193] [Examples 1-4]

[0194] [ka]

[0195] Compound (p3) (8.0 g) was dissolved in acetonitrile (40 g). Then, piperidine (0.86 g) was added, and the mixture was reacted at room temperature under a nitrogen atmosphere for 2 hours. After the reaction was completed, 20% saline (80 g) was added, and the mixture was stirred at room temperature for 15 minutes to wash. After separating the organic layer and the aqueous layer, 20% saline (80 g) was added to the organic layer again, and the mixture was stirred at room temperature for 15 minutes to wash, and the organic layer was collected. The obtained organic layer was concentrated at 40°C, and toluene (200 g) and magnesium sulfate (10 g) were added to the concentrate, and the mixture was dehydrated by stirring at room temperature for 30 minutes, and then suction filtered using 5A filter paper. Hexane (100 g) was added to the obtained filtrate, and the mixture was stirred at room temperature for 15 minutes to precipitate the product. The mixture was suction filtered using 5A filter paper, and the precipitate was collected, washed with hexane (100 g), suction filtered using 5A filter paper, and vacuum dried to obtain the above compound (p4). Yield: 7.2 g. HPLC: amine purity 92%. 1 H-NMR(d6-DMSO): 1.62ppm(m, 2H, -CO-NH-CH2- CH 2-CH2-O-(CH2-CH2-O)j-CH3), 1.64ppm(broad, 1H), 2.59ppm(dd, 1H, -NH-CO-CH- CH 2-C6H5), 2.98ppm(dd, 1H, -NH-CO-CH- CH 2-C6H5), 3.10ppm(q, 2H, -CO-NH- CH2-CH2-CH2-O-(CH2-CH2-O)j-CH3), 3.24ppm(s, 3H, -CO-NH-CH2-CH2-CH2-O-(CH2-CH2-O)j- CH 3), 3.48ppm(m, approx. 1,900H, -CO-NH-CH2-CH2-CH2-O-( CH 2 -CH 2-O)j-CH3), 7.24ppm(m, 6H, -NH-CO-CH-CH2- C 6 H 5, -NH-), 7.73ppm (t, 1H), 8.12ppm (broad, 1H)

[0196] [Examples 1-5]

[0197] [ka]

[0198] The compound (p4) (6.0 g) obtained in Example 1-4, sodium acetate (49 mg), and glutaric anhydride (51 mg) were dissolved in toluene (25 g) and reacted at 40° C. for 7 hours under a nitrogen atmosphere. After the reaction was completed, the mixture was diluted with toluene (20 g) and suction filtered using 5A filter paper. Hexane (30 g) was added to the obtained filtrate and stirred at room temperature for 15 minutes to precipitate the product. The precipitate was collected by suction filtration using 5A filter paper. The obtained precipitate was dissolved in ethyl acetate (100 g), hexane (50 g) was added, and stirred at room temperature for 15 minutes to precipitate the product. The precipitate was collected by suction filtration using 5A filter paper, washed with hexane (50 g), suction filtered using 5A filter paper, and vacuum dried to obtain the above compound (p5). Yield 4.8 g. 1 H-NMR(d6-DMSO): 1.62ppm(m, 2H, -CO-NH-CH2- CH 2-CH2-O-(CH2-CH2-O)j-CH3), 1.64ppm(broad, 1H), 2.05ppm(dd, 2H, -NH-CO-CH2- CH 2-CH2-COOH)2.30ppm(m, 4H, -NH-CO- CH 2-CH2- CH2-COOH), 2.59ppm(dd, 1H, -NH-CO-CH- CH 2-C6H5), 2.98ppm(dd, 1H, -NH-CO-CH- CH 2-C6H5), 3.10ppm(q, 2H, -CO-NH- CH 2-CH2-CH2-O-(CH2-CH2-O)j-CH3), 3.24ppm(s, 3H, -CO-NH-CH2-CH2-CH2-O-(CH2-CH2-O)j- CH 3), 3.48ppm(m, approx. 1,900H, -CO-NH-CH2-CH2-CH2-O-( CH 2 -CH 2-O)j-CH3), 7.24ppm(m, 6H, -NH-CO-CH-CH2- C 6 H 5, -NH-), 7.73ppm (t, 1H), 8.12ppm (broad, 1H)

[0199] [Examples 1-6]

[0200] [ka]

[0201] The compound (p5) (4.5 g) obtained in Example 1-5 and N-hydroxysuccinimide (103 mg) were dissolved in toluene (25 g). Then, dicyclohexylcarbodiimide (139 mg) was added, and the mixture was reacted at 40° C. under a nitrogen atmosphere for 3 hours. After the reaction was completed, toluene (50 g) was added to dilute the mixture, and the mixture was suction-filtered using 5A filter paper. Hexane (50 g) was added to the obtained filtrate, and the mixture was stirred at room temperature for 15 minutes to precipitate the product. The mixture was suction-filtered using 5A filter paper, the precipitate was collected, and then dissolved in ethyl acetate (100 g), hexane (50 g) was added, and the mixture was stirred at room temperature for 15 minutes to precipitate the product. The mixture was suction-filtered using 5A filter paper, the precipitate was collected, and then washed with hexane (50 g), suction-filtered using 5A filter paper, and vacuum-dried to obtain the above compound (p6). Yield: 3.5 g. The purity of the active ester is 98% ( 1 H-NMR). 1H-NMR (d6-DMSO): 1.62 ppm (m, 2H, -CO-NH-CH2- CH 2-CH2-O-(CH2-CH2-O)j-CH3), 1.64 ppm (broad, 1H), 2.05 ppm (dd, 2H, -NH-CO-CH2- CH 2-CH2-CO-), 2.30 ppm (m, 4H, -NH-CO- CH 2-CH2- CH 2-COO-), 2.59 ppm (dd, 1H, -NH-CO-CH- CH 2-C6H5), 2.72 ppm (s, 4H, -CO- CH 2 -CH 2-CO-), 2.98 ppm (dd, 1H, -NH-CO-CH- CH 2-C6H5), 3.10 ppm (q, 2H, -CO-NH- CH 2-CH2-CH2-O-(CH2-CH2-O)j-CH3), 3.24 ppm (s, 3H, -CO-NH-CH2-CH2-CH2-O-(CH2-CH2-O)j- CH 3), 3.48 ppm (m, approximately 1,900H, -CO-NH-CH2-CH2-CH2-O-( CH 2 -CH 2-O)j-CH3), 7.24 ppm (m, 6H, -NH-CO-CH-CH2- C 6 H 5, -NH-), 7.73 ppm (t, 1H), 8.12 ppm (broad, 1H)

[0202] [Example 1-7]

[0203] [Chemical formula]

[0204] Compound (p2) (3.0 g) obtained in Example 1-2 and compound (p6) (3.0 g) obtained in Example 1-6 were dissolved in dichloromethane (60 g), and triethylamine (95 mg) was added and reacted at room temperature for 8 hours. After the reaction, 20% saline (50 g) was added, and the reaction solution was washed, and the organic layer was collected. Magnesium sulfate (10 g) was added to the organic layer, and the solution was stirred at room temperature for 15 minutes, and then suction filtered using 5A filter paper. The obtained filtrate was concentrated, and the concentrate was dissolved in ethyl acetate (100 g), hexane (50 g) was added, and the solution was stirred at room temperature for 15 minutes to precipitate the product. The solution was suction filtered using 5A filter paper, and the precipitate was collected, and then dissolved again in ethyl acetate (100 g), and hexane (50 g) was added, and the solution was stirred at room temperature for 15 minutes to precipitate the product. The precipitate was collected by suction filtration using 5A filter paper, washed with hexane (50 g) containing 2,6-di-tert-butyl-p-cresol (BHT) (10 mg), suction filtration using 5A filter paper, and vacuum dried to obtain the above compound (p7). Yield: 4.2 g. HPLC: carboxylic acid purity is 95%. 1 H-NMR(d6-DMSO): 1.62ppm(m, 2H, CO-NH-CH2- CH 2-CH2-O-(CH2-CH2-O)j-CH3), 1.64ppm(broad, 1H), 2.05ppm(dd, 2H, -NH-CO-CH2- CH 2-CH2-CO-), 2.30ppm(m, 4H, -NH-CO- CH 2-CH2- CH 2-CO-), 2.59ppm(dd, 1H, -NH-CO-CH- CH 2-C6H5), 2.98ppm(dd, 1H, -NH-CO-CH- CH 2-C6H5), 3.24ppm(s, 3H, -NH-CH2-CH2-(O-CH2-CH2)jO- CH 3), 3.48ppm(m, approx. 3,800H, -CH2-NH-CH2-CH2-(O- CH 2 -CH 2)jO-CH3), 4.61 ppm (- CH 2-COOH), 7.24ppm(m, 6H, -NH-CO-CH-CH2-C 6 H 5, -NH-), 7.73ppm(t, 1H), 8.12ppm(broad, 1H))

[0205] [Example 2]

[0206] [ka]

[0207] The compound (p7) (2.0 g) obtained in Example 1-7 and N-Fmoc-ethylenediamine (32 mg) were dissolved in acetonitrile (5.0 g). Then, diisopropylethylamine (16 mg) and DMT-MM (415 mg) were added, and the mixture was reacted at room temperature under a nitrogen atmosphere for 2 hours. Then, piperidine (107 mg) was added, and the mixture was reacted at room temperature under a nitrogen atmosphere for 2 hours. After the reaction was completed, the mixture was concentrated, and the concentrate was redissolved in chloroform (50 g), 20% saline (25 g) was added, and the mixture was stirred at room temperature for 15 minutes to wash, and the organic layer was recovered. Magnesium sulfate (10 g) was added to the obtained organic layer, and the mixture was dehydrated by stirring at room temperature for 30 minutes, and then suction filtered using 5A filter paper. The obtained filtrate was concentrated at 40° C., toluene (100 g) was added to the concentrate to dissolve it, and hexane (50 g) was added and stirred at room temperature for 15 minutes to precipitate the product. The precipitate was collected by suction filtration using 5A filter paper, washed with hexane (30 g) containing 6 mg of BHT, suction filtration using 5A filter paper, and vacuum dried to obtain the above compound (p8). Yield: 1.3 g. HPLC: Amine purity 93%. 1 H-NMR(d6-DMSO): 1.62ppm(m, 2H, CO-NH-CH2- CH 2-CH2-O-(CH2-CH2-O)j-CH3), 1.64ppm(broad, 1H), 2.05ppm(dd, 2H, -NH-CO-CH2- CH 2-CH2-CO-), 2.30ppm(m, 4H, -NH-CO- CH 2-CH2- CH 2-CO-), 2.59ppm(dd, 1H, -NH-CO-CH- CH2-C6H5), 2.76ppm(m, 2H, -NH-CH2- CH 2-NH2), 2.98ppm(dd, 1H, -NH-CO-CH- CH 2-C6H5), 3.24ppm(s, 3H, -NH-CH2-CH2-(O-CH2-CH2)jO- CH 3), 3.48ppm(m, approx. 3,800H, -CH2-NH-CH2-CH2-(O- CH 2 -CH 2)jO-CH3), 7.24ppm(m, 6H, -NH-CO-CH-CH2- C 6 H 5, -NH-), 7.73ppm(t, 1H), 7.80ppm(broad, 1H), 8.12ppm(broad, 1H)

[0208] [Example 3]

[0209] [ka]

[0210] The compound (p7) (300 mg) obtained in Example 1-7 was dissolved in acetonitrile (2 g). Then, N-hydroxysuccinimide (6 mg) and dicyclohexylcarbodiimide (6 mg) were added, and the mixture was reacted at 40° C. under a nitrogen atmosphere for 3 hours. Then, triethylamine (3 mg) and N-(2-aminoethyl)maleimide hydrochloride (5 mg) were added, and the mixture was reacted at 40° C. under a nitrogen atmosphere for 3 hours. After the reaction was completed, the mixture was concentrated, and the concentrate was dissolved in ethyl acetate (50 g), and hexane (30 g) was added and stirred at room temperature for 15 minutes to precipitate the product. The precipitate was collected by suction filtration using 5A filter paper, and then dissolved again in ethyl acetate (50 g), and hexane (30 g) was added and stirred at room temperature for 15 minutes to precipitate the product. The precipitate was collected by suction filtration using 5A filter paper, washed with hexane (30 g) containing BHT (6 mg), suction filtered using 5A filter paper, and dried in vacuum to obtain the above compound (p9). Yield: 264 mg. The maleimide purity was 92% ( 1 H-NMR). 11H-NMR (d6-DMSO): 1.62 ppm (m, 2H, CO-NH-CH2- CH 2-CH2-O-(CH2-CH2-O)j-CH3), 1.64 ppm (broad, 1H), 2.05 ppm (dd, 2H, -NH-CO-CH2- CH 2-CH2-CO-), 2.30 ppm (m, 4H, -NH-CO- CH 2-CH2- CH 2-CO-), 2.59 ppm (dd, 1H, -NH-CO-CH- CH 2-C6H5), 2.66 ppm (t, 2H, -NH-CO- CH 2-CH2-Maleimide), 2.98 ppm (dd, 1H, -NH-CO-CH- CH 2-C6H5), 3.24 ppm (s, 3H, -NH-CH2-CH2-(O-CH2-CH2)j-O- CH 3), 3.48 ppm (m, approximately 3,800H, -CH2-NH-CH2-CH2-(O- CH 2 -CH 2)j-O-CH3), 4.76 ppm (t, 2H, -NH-CO-CH2- CH 2-Maleimide), 6.98 ppm (s, 2H, -CO- CH-CH -CO-), 7.24 ppm (m, 6H, -NH-CO-CH-CH2- C 6 H 5, -NH-), 7.73 ppm (t, 1H), 7.80 ppm (broad, 1H), 8.01 ppm (broad, 1H), 8.12 ppm (broad, 1H)

[0211] [Example 4]

[0212] [Chemical formula]

[0213] Toluene (6 g) was added to the compound (p7) (1.2 g) obtained in Example 1-7, and the mixture was dissolved by heating at 40°C. Then, N-hydroxysuccinimide (24 mg) and dicyclohexylcarbodiimide (24 mg) were added, and the mixture was reacted at 40°C under a nitrogen atmosphere for 3 hours. After the reaction was completed, the mixture was suction filtered using 5A filter paper, and the obtained filtrate was diluted with ethyl acetate (100 g), hexane (50 g) was added, and the mixture was stirred at room temperature for 30 minutes to precipitate the product. The mixture was suction filtered using 5A filter paper, and the precipitate was collected, washed with hexane (50 g) containing BHT (10 mg), suction filtered using 5A filter paper, and vacuum dried to obtain the above compound (p10). Yield: 1.0 g. The purity of the active ester was 91% ( 1 H-NMR). 1 H-NMR(d6-DMSO): 1.62ppm(m, 2H, CO-NH-CH2- CH 2-CH2-O-(CH2-CH2-O)j-CH3), 1.64ppm(broad, 1H), 2.05ppm(dd, 2H, -NH-CO-CH2- CH 2-CH2-CO-), 2.30ppm(m, 4H, -NH-CO- CH 2-CH2- CH 2-CO-), 2.59ppm(dd, 1H, -NH-CO-CH- CH 2-C6H5), 2.72ppm(s, 4H, -CO- CH 2 -CH 2-CO-), 2.98ppm(dd, 1H, -NH-CO-CH- CH 2-C6H5), 3.24ppm(s, 3H, -NH-CH2-CH2-(O-CH2-CH2)jO- CH 3), 3.48ppm(m, approx. 3,800H, -CH2-NH-CH2-CH2-(O- CH 2 -CH 2)jO-CH3), 4.61 ppm (- CH 2-OCO-Succinimide), 7.24ppm(m, 6H, -NH-CO-CH-CH2- C 6 H 5, -NH-), 7.73ppm (t, 1H), 8.12ppm (broad, 1H)

[0214] [Example 5]

[0215] [ka]

[0216] [Example 5-1]

[0217] [ka]

[0218] The compound (p7) (800 mg) obtained in Example 1-7 was dissolved in toluene (7 g) at 40°C by heating, and then 3-aminopropionaldehyde diethyl acetal (9 mg) was added and reacted at 50°C under a nitrogen atmosphere for 2 hours. After the reaction was completed, ethyl acetate (100 g) was added, stirred until homogenous, hexane (50 g) was added, and stirred at room temperature for 15 minutes to precipitate the product. The precipitate was collected by suction filtration using 5A filter paper, washed with hexane (50 g) containing BHT (10 mg), suction filtration using 5A filter paper, and vacuum dried to obtain the above compound (p11). Yield: 684 mg. 1 H-NMR(d6-DMSO): 1.20ppm(t, 6H( CH 3-CH2-O)2-CH-)1.62ppm(m, 2H, CO-NH-CH2- CH 2-CH2-O-(CH2-CH2-O)j-CH3), 1.64ppm(broad, 1H), 1.85ppm(dd, 2H, -NH-CH2- CH 2-CH-(O-CH2-CH3)2), 2.05ppm(dd, 2H, -NH-CO-CH2- CH 2-CH2-CO-), 2.30ppm(m, 4H, -NH-CO- CH 2-CH2- CH 2-CO-), 2.59ppm(dd, 1H, -NH-CO-CH- CH 2-C6H5), 2.98ppm(dd, 1H, -NH-CO-CH- CH 2-C6H5), 3.24ppm(s, 3H, -NH-CH2-CH2-(O-CH2-CH2)jO- CH 3), 3.48ppm(m, approx. 3,800H, -CH2-NH-CH2-CH2-(O- CH 2 -CH 2)jO-CH3), 3.91 ppm (- CH 2-CO-NH-CH2-CH2-CH-(O-CH2-CH3)2), 4.55ppm(t, 1H, - CH -(O-CH2-CH3)2)7.24ppm(m, 6H, -NH-CO-CH-CH2- C 6 H 5, -NH-), 7.73ppm (t, 1H), 8.12ppm (broad, 1H)

[0219] [Example 5-2]

[0220] [ka]

[0221] The compound (p11) (600 mg) obtained in Example 5-1 was dissolved in a phosphate buffer solution (6.0 g) adjusted to pH 1.90, and reacted at room temperature under a nitrogen atmosphere for 3 hours. After the reaction, 0.1 N sodium hydroxide aqueous solution was added, the pH was adjusted to 6.5, and then sodium chloride (1.5 g) was added and dissolved. 0.1 N sodium hydroxide aqueous solution was added to the obtained solution, the pH was adjusted to 7.10, and then chloroform (10 g) containing BHT (2 mg) was added and stirred at room temperature for 20 minutes, and the product was extracted into the organic layer. The organic layer and the aqueous layer were separated, the organic layer was recovered, and then chloroform (20 g) containing BHT (4 mg) was added again to the aqueous layer and stirred at room temperature for 20 minutes, and the product was extracted into the organic layer. The organic layers obtained in the first and second extractions were combined and concentrated at 40° C., and the obtained concentrate was dissolved in ethyl acetate (50 g), hexane (30 g) was added, and the mixture was stirred at room temperature for 15 minutes to precipitate the product. The precipitate was collected by suction filtration using 5A filter paper, washed with hexane (30 g) containing BHT (6 mg), suction filtered using 5A filter paper, and dried in vacuum to obtain the above compound (p12). Yield: 457 mg. The aldehyde purity was 90% ( 1 H-NMR). 1H-NMR(d6-DMSO):1.62ppm(m,2H,CO-NH-CH2- CH 2-CH2-O-(CH2-CH2-O)j-CH3), 1.64ppm (broad, 1H), 2.05ppm (dd, 2H, -NH-CO-CH2- CH 2-CH2-CO-), 2.30ppm(m, 4H, -NH-CO- CH 2-CH2- CH 2-CO-), 2.59ppm(dd, 1H, -NH-CO-CH- CH 2-C6H5), 2.66ppm (dd, 2H, -CO-NH-CH2- CH 2-CHO), 2.98ppm (dd, 1H, -NH-CO-CH- CH 2-C6H5), 3.24ppm(s, 3H, -NH-CH2-CH2-(O-CH2-CH2)jO- CH 3) 3.48ppm(m, about 3,800H, -CH2-NH-CH2-CH2-(O- CH 2 -CH 2)jO-CH3), 3.91ppm (s, 2H, - CH 2-CO-NH-CH2-CH2-CHO)7.24ppm(m,6H,-NH-CO-CH-CH2- C 6 H 5. -NH-), 7.73ppm (t, 1H), 8.12ppm (broad, 1H), 9.72ppm (s, 1H, -CO-NH-CH2-CH2- GIVE )

[0222] [Example 6]

[0223]

change

[0224] [Example 6-1]

[0225]

change

[0226] Acetonitrile (10 g) was added to L-glutamic acid (Fmoc-Glu-OH) (16.0 mg) whose N-terminus was protected with a 9-fluorenylmethyloxycarbonyl group (Fmoc group) and the compound (p4) (2.0 g) obtained in Example 1-4, and the mixture was dissolved by heating at 30°C. Then, diisopropylethylamine (15 mg) and DMT-MM (39.0 mg) were added, and the mixture was reacted at room temperature under a nitrogen atmosphere for 1 hour. Then, piperidine (111 mg) was added, and the mixture was reacted at room temperature under a nitrogen atmosphere for 2 hours. After the reaction was completed, the reaction solution was diluted with toluene (80 g), hexane (40 g) was added, and the mixture was stirred at room temperature for 15 minutes to precipitate the product. The mixture was filtered by suction using 5A filter paper, and the precipitate was collected, and then the mixture was dissolved again in toluene (100 g), hexane (50 g) was added, and the mixture was stirred at room temperature for 15 minutes to precipitate the product. The precipitate was collected by suction filtration using 5A filter paper, washed with hexane (50 g) containing BHT (10 mg), suction filtration using 5A filter paper, and vacuum dried to obtain the above compound (p13). Yield: 1.6 g. HPLC: amine purity 92%. 1 H-NMR(d6-DMSO): 1.54ppm(m, 2H, -NH-CO-CH(NH2)- CH 2-CH2-), 1.62ppm(m, 4H, -CO-NH-CH2- CH 2-CH2-), 1.97ppm(m, 2H, -NH-CO-CH(NH2)-CH2- CH 2-), 2.74ppm(dd, 1H, -CO-NH-CH- CH 2-C6H5), 2.81ppm(dd, 1H, -CO-NH-CH- CH 2-C6H5), 3.11ppm(m, 11H), 3.24ppm(s, 6H, -CO-NH-CH2-CH2-CH2-O-(CH2-CH2-O)j- CH 3), 3.64ppm(m, approx. 3,800H, -CO-NH-CH2-CH2-CH2-O-( CH 2 -CH 2-O)j-CH3), 4.49ppm(m, 1H, -CO-NH- CH -CH2-C6H5), 4.57ppm(m, 1H, -CO-NH- CH-CH2-C6H5), 7.25ppm(m, 10H, -CO-NH-CH-CH2- C 6 H 5), 7.74ppm(m, 2H), 8.44ppm(m, 2H), 8.61ppm(m, 2H)

[0227] [Example 6-2]

[0228] [ka]

[0229] ε-caprolactone (114 mg) was dissolved in 1N NaOH (0.8 mL) and reacted for 2 hours to prepare a 6-hydroxycaproic acid aqueous solution (0.88 M). Compound (p13) (1.5 g) obtained in Example 6-1 was dissolved in acetonitrile (6 g). Then, the above 6-hydroxycaproic acid aqueous solution (80 μL), diisopropylethylamine (15 mg), and DMT-MM (16 mg) were added and reacted at room temperature under a nitrogen atmosphere for 1 hour. After the reaction was completed, the reaction solution was concentrated at 40° C., and chloroform (30 g) was added to the obtained concentrate and dissolved. A saturated aqueous sodium bicarbonate solution (15 g) was added and stirred at room temperature for 15 minutes to wash. After separating the aqueous layer and the organic layer, a saturated aqueous sodium bicarbonate solution (15 g) was added to the organic layer again, and the organic layer was washed by stirring at room temperature for 15 minutes, and the organic layer was recovered. Magnesium sulfate (5 g) was added to the obtained chloroform solution, and the mixture was stirred for 30 minutes to dehydrate, and then suction filtration was performed using 5A filter paper. The obtained filtrate was concentrated at 40°C, and ethyl acetate (50 g) was added to the concentrate and stirred until homogeneous. Then, hexane (25 g) was added and stirred at room temperature for 15 minutes to precipitate the product. After suction filtration using 5A filter paper and recovery of the precipitate, the mixture was dissolved again in ethyl acetate (50 g), hexane (25 g) was added, and the mixture was stirred at room temperature for 15 minutes to precipitate the product. After suction filtration using 5A filter paper and recovery of the precipitate, the mixture was washed with hexane (50 g) containing BHT (10 mg), suction filtration using 5A filter paper, and vacuum drying to obtain the above compound (p14). Yield: 1.2 g. 11H-NMR (CDCl3): 1.37 ppm (m, 2H, HO-CH2-CH2- CH 2-CH2-CH2-CO-NH-), 1.55 ppm (m, 4H, HO-CH2- CH 2-CH2- CH 2-CH2-CO-NH-), 1.77 ppm (m, 4H, -CO-NH-CH2- CH 2-CH2-O-(CH2-CH2-O)j-CH3), 1.85 ppm (m, 1H), 2.01 ppm (m, 2H, HO-CH2-CH2-CH2-CH2- CH 2-CO-NH-), 3.01 ppm (m, 1H), 3.24 ppm (m, 8H), 3.38 ppm (s, 6H, -CO-NH-CH2-CH2-CH2-O-(CH2-CH2-O)j- CH 3), 3.64 ppm (m, about 3,800H, -CO-NH-CH2-CH2-CH2-O-( CH 2 -CH 2-O)j-CH3), 4.03 ppm (m, 4H), 4.14 ppm (m, 1H), 4.48 ppm (m, 2H, -CO-NH- CH -CH2-C6H5), 6.95 ppm (broad, 1H), 7.00 ppm (broad, 1H), 7.26 ppm (m, 10H, -CO-NH-CH-CH2- C 6 H 5), 7.66 ppm (broad, 1H), 8.29 ppm (broad, 1H)

[0230] [Example 6-3]

[0231] [Chemical formula]

[0232] The compound (p14) (500 mg) obtained in Example 6-2 was dissolved in dichloromethane (3.5 g). Then, di(N-succinimidyl) carbonate (51 mg) and pyridine (20 mg) were added, and the mixture was reacted at room temperature under a nitrogen atmosphere for 8 hours. After the reaction was completed, the reaction solution was washed with 5% saline (5 g), magnesium sulfate (0.1 g) was added, and the mixture was stirred at 25°C for 30 minutes, and then suction filtration was performed using 5A filter paper. The obtained filtrate was concentrated, and ethyl acetate (100 g) was added to the concentrate to dissolve it, and then hexane (50 g) was added and stirred at room temperature for 15 minutes to precipitate the product. The precipitate was collected by suction filtration using 5A filter paper, washed with hexane (25 g) containing BHT (5 mg), suction filtration using 5A filter paper, and vacuum dried to obtain the above compound (p15). Yield: 286 mg. The purity of the active carbonate was 91% ( 1 H-NMR) 1 H-NMR(CDCl3):1.38ppm(m, 2H, Succinimide-OCO-CH2-CH2- CH 2-CH2-CH2-CO-NH-), 1.59ppm(m, 2H, Succinimide-OCO-CH2-CH2-CH2- CH 2-CH2-CO-NH-), 1.75ppm(m, 6H), 1.85ppm(m, 1H), 2.13ppm(m, 2H, Succinimide-OCO-CH2-CH2-CH2-CH2- CH 2-CO-NH-), 2.83ppm(s, 4H, -CO- CH 2 -CH 2-CO-), 3.01ppm(m, 1H), 3.19ppm(m, 6H), 3.38ppm(s, 6H, -CO-NH-CH2-CH2-CH2-O-(CH2-CH2-O)j- CH 3), 3.64ppm(m, approx. 3,800H, -CO-NH-CH2-CH2-CH2-O-( CH 2 -CH 2-O)j-CH3), 4.03ppm(m, 3H), 4.18ppm(m, 1H), 4.31ppm(t, 2H, Succinimide-OCO- CH 2-CH2-CH2-CH2-CH2-CO-NH-), 4.50ppm(m, 2H, -CO-NH- CH-CH2-C6H5), 6.98ppm(broad, 1H), 7.15ppm(broad, 1H), 7.26ppm(m, 10H, -CO-NH-CH-CH2- C 6 H 5), 7.81ppm (broad, 1H), 8.37ppm (broad, 1H)

[0233] [Example 6-4]

[0234] [ka]

[0235] Compound (p2) (125 mg) obtained in Example 1-2 and compound (p15) (250 mg) obtained in Example 6-3 were dissolved in dichloromethane (50 g), and triethylamine (0.5 g) was added and reacted at room temperature for 8 hours. After the reaction, 20% saline (20 g) was added, and the reaction solution was washed, and the organic layer was collected. Magnesium sulfate (5 g) was added to the organic layer, and the reaction solution was stirred at room temperature for 15 minutes, and then suction filtered using 5A filter paper. The obtained filtrate was concentrated, and the concentrate was dissolved in ethyl acetate (100 g), hexane (50 g) was added, and the reaction solution was stirred at room temperature for 15 minutes, and the product was precipitated. The precipitate was collected by suction filtration using 5A filter paper, washed with hexane (20 g) containing BHT (4 mg), suction filtration using 5A filter paper, and vacuum dried to obtain the above compound (p16). Yield 242 mg. HPLC: carboxylic acid purity is 90% 1 H-NMR(d6-DMSO): 1.29ppm(m, 2H, -NH-CO-CH2-CH2- CH 2-CH2-CH2-OCO-), 1.58ppm(m, 4H, -NH-CO-CH2- CH 2-CH2- CH 2-CH2-OCO-), 1.75ppm(m, 6H), 1.85ppm(m, 1H), 2.13ppm(m, 2H, -NH-CO- CH2-CH2-CH2-CH2-CH2-OCO-), 3.01ppm (m, 1H), 3.19ppm (m, 6H), 3.38ppm (s, 6H, -CO-NH-CH2-CH2-CH2-O-(CH2-CH2-O)j- CH 3) 3.64ppm(m, about 5,700H, -CO-NH-CH2-CH2-CH2-O-( CH 2 -CH 2-O)j-CH3), 3.90ppm(t, 2H, -NH-CO-CH2-CH2-CH2-CH2- CH 2-OCO-)4.03ppm (m, 3H), 4.18ppm (m, 1H), 4.37ppm (s, 2H, - CH 2-COOH) 4.50ppm (m, 2H, -CO-NH- CH -CH2-C6H5), 6.98ppm (broad, 1H), 7.15ppm (broad, 1H), 7.26ppm (m, 10H, -CO-NH-CH-CH2- C 6 H 5), 7.81ppm (broad, 1H), 8.37ppm (broad, 1H)

[0236] [Comparative Example 1]

[0237]

change

[0238] [Comparative Example 1-1]

[0239]

change

[0240] The compound (1g) obtained in Example 1-2 and NOF Corp.'s "SUNBRIGHT ME-200GS3" (1g) having an average molecular weight of 20,000 were dissolved in dichloromethane (20g), and triethylamine (0.2g) was added and reacted at room temperature for 8 hours. After the reaction, 20% saline (10g) was added, and the reaction solution was washed, and the organic layer was collected. Magnesium sulfate (3g) was added to the organic layer, and the solution was stirred at room temperature for 15 minutes, and then suction filtered using 5A filter paper. The obtained filtrate was concentrated, and the concentrate was dissolved in ethyl acetate (100g), hexane (50g) was added, and the solution was stirred at room temperature for 15 minutes to precipitate the product. The precipitate was collected by suction filtration using 5A filter paper, washed with hexane (30g) containing BHT (6mg), suction filtered using 5A filter paper, and vacuum dried to obtain the above compound (p17). Yield: 1.2g. HPLC: carboxylic acid purity is 93%. 1 H-NMR(d6-DMSO): 1.73ppm(m, 2H, -CO-NH-CH2- CH 2-CH2-(O-CH2-CH2)j-), 2.03ppm(m, 2H, -NH-CO-CH2- CH 2-CH2-CO-N-), 2.34ppm(t, 4H, -NH-CO- CH 2-CH2- CH 2-CO-N-), 3.40ppm(s, 6H, -(O-CH2-CH2)jO- CH 3), 3.55ppm(m, approx. 3,800H, -CH2-(O- CH 2 -CH 2)jO-CH3), 4.61ppm(s, 2H, - CH 2-COOH), 7.70ppm(broad, 1H, -CH2- NH -CO-CH2-CH2-CH2-CO-)

[0241] [Comparative Example 1-2]

[0242] [ka]

[0243] The compound (p17) (1.0 g) obtained in Comparative Example 1-1 and N-Fmoc-ethylenediamine (16 mg) were dissolved in acetonitrile (2.5 g). Then, diisopropylethylamine (8 mg) and DMT-MM (208 mg) were added, and the mixture was reacted at room temperature under a nitrogen atmosphere for 2 hours. Then, piperidine (107 mg) was added, and the mixture was reacted at room temperature under a nitrogen atmosphere for 2 hours. After the reaction was completed, the mixture was concentrated, and the concentrate was redissolved in chloroform (50 g), 20% saline (25 g) was added, and the mixture was stirred at room temperature for 15 minutes to wash, and the organic layer was recovered. Magnesium sulfate (10 g) was added to the obtained organic layer, and the mixture was dehydrated by stirring at room temperature for 30 minutes, and then suction filtered using 5A filter paper. The obtained filtrate was concentrated at 40° C., toluene (100 g) was added to the concentrate to dissolve it, and hexane (50 g) was added and stirred at room temperature for 15 minutes to precipitate the product. The precipitate was collected by suction filtration using 5A filter paper, washed with hexane (30 g) containing 6 mg of BHT, suction filtration using 5A filter paper, and vacuum dried to obtain the above compound (p8). Yield: 581 mg. HPLC: Amine purity is 90%. 1 H-NMR(d6-DMSO): 1.73ppm(m, 2H, -CO-NH-CH2- CH 2-CH2-(O-CH2-CH2)j-), 2.03ppm(m, 2H, -NH-CO-CH2- CH 2-CH2-CO-N-), 2.34ppm(t, 4H, -NH-CO- CH 2-CH2- CH 2-CO-N-), 2.76ppm(m, 2H, -CH2-CO-NH-CH2- CH 2-NH2), 3.40ppm(s, 6H, -(O-CH2-CH2)jO- CH 3), 3.55ppm(m, approx. 3,800H, -CH2-(O- CH 2 -CH 2)jO-CH3), 3.66ppm(m, 2H, -CH2-CO-NH- CH 2-CH2-NH2), 3.91ppm(s, 2H, -N- CH 2-CO-NH-), 7.70ppm(broad, 1H, -CH2- NH-CO-CH2-CH2-CH2-CO-), 7.83ppm(broad, 1H, -CH2-CO- NH -CH2-CH2-NH2)

[0244] [Example 8] Stability test in serum 1 mL of mouse or human serum was added to a 1.5 mL Eppendorf tube, and the compound (p8) which is a branched degradable polyethylene glycol derivative obtained in Example 2, the compound (p18) which is a non-degradable polyethylene glycol derivative obtained in Comparative Example 1-2, and methoxy PEG amine 40 kDa were added to each to a concentration of 5.0 mg / mL. After 96 hours of incubation at 37°C, 200 μL was sampled, acetonitrile was added thereto, and the mixture was stirred with a vortex for 1 minute to precipitate proteins in the serum, and the supernatant was collected after centrifugation. Next, in order to remove hydrophobic substances such as fatty acids, hexane was added to the collected solution, which was stirred with a vortex for 1 minute and centrifuged to collect the lower layer. This solution was concentrated under vacuum conditions to collect the polyethylene glycol derivative from the serum. Then, GPC analysis was performed to calculate the decomposition rate of the degradable polyethylene glycol derivative. The decomposition rate was calculated using the following formula. Decomposition rate = (40 kDa peak area% before test - 40 kDa peak area% after test) ÷ (40 kDa peak area% before test) × 100 The results are shown in Table 1.

[0245] [Table 1]

[0246] According to Table 1, compound (p8), which is a branched degradable polyethylene glycol derivative, was not degraded in serum, similar to compound (p18) and methoxy PEG amine 40 kDa, which are non-degradable polyethylene glycol derivatives. In other words, it was shown that the degradable polyethylene glycol derivative is stable in blood.

[0247] [Example 9] Degradation test using cells 10 x 106 cells of RAW264.7 were seeded on a 100 mm dish using 10 mL of RPMI-1640 medium (10% FBS Pn / St), and cultured at 37°C for 24 hours. The medium was replaced with a medium in which the compound (p8) which is a branched degradable polyethylene glycol derivative obtained in Example 2, the compound (p18) which is a non-degradable polyethylene glycol derivative obtained in Comparative Example 1-2, and methoxy PEG amine 40 kDa were dissolved to a concentration of 10 mg / mL, and cultured at 37°C for 96 hours. After culture, the cells were dissolved in a 1% SDS solution, diluted with PBS, acetonitrile was added thereto, and the mixture was stirred with a vortex for 1 minute to precipitate proteins in the cell lysate, and the supernatant was collected after centrifugation. Next, in order to remove hydrophobic substances such as fatty acids, hexane was added to the collected solution, which was stirred with a vortex for 1 minute, and the lower layer was collected after centrifugation. This solution was concentrated under vacuum conditions, and the polyethylene glycol derivative was collected from the cells. In addition, to confirm decomposition in the medium used for cell culture, various polyethylene glycol derivatives were dissolved in the medium to a concentration of 10 mg / mL, and the cells were cultured at 37°C for 96 hours, and the polyethylene glycol derivatives were recovered using the same procedure as above. Thereafter, the various polyethylene glycol derivatives thus recovered were subjected to GPC analysis, and the decomposition rates of the branched degradable polyethylene glycol derivatives were calculated using the same calculation formula as in Example 8. The results are shown in Table 2.

[0248] [Table 2]

[0249] According to Table 2, it was confirmed that compound (p8), a branched degradable polyethylene glycol derivative, was effectively degraded within the cells (degradation rate 99%), degrading from a molecular weight of 40,000 to 20,000. Since the branched degradable polyethylene glycol derivative was not degraded in the medium used in cell culture, it was confirmed that it was specifically degraded within the cells. On the other hand, no degradation was observed within the cells for either compound (p18), a non-degradable polyethylene glycol derivative, or methoxy PEG amine 40 kDa. [Industrial Applicability]

[0250] The branched degradable polyethylene glycol derivative of the present invention is a high molecular weight polyethylene glycol derivative that does not cause cellular vacuoles, can be effectively used for modifying biologically relevant substances, is stable in the blood of the living body, and is degraded within the cells.

Claims

1. A branched degradable polyethylene glycol derivative represented by the following formula (1), which has an oligopeptide in its molecule that is degraded within a cell. [Formula 1] (In the formula, k 1 and k 2 j is independently 1 to 12; 1 and j 2 are each independently 45 to 950, R is a hydrogen atom, a substituted or unsubstituted alkyl group having 1 to 12 carbon atoms, a substituted aryl group, an aralkyl group, or a heteroalkyl group, Z is an oligopeptide that is decomposed by an intracellular enzyme, X is a functional group capable of reacting with a biologically relevant substance, and L 1 and L 2 are each independently a single bond or a divalent spacer.

2. 2. The branched degradable polyethylene glycol derivative according to claim 1, wherein the oligopeptide Z is a degradable oligopeptide having 2 to 8 residues consisting of neutral amino acids excluding cysteine.

3. 3. The branched degradable polyethylene glycol derivative according to any one of claims 1 to 2, wherein the oligopeptide Z is a peptide having glycine as the C-terminal amino acid.

4. The branched degradable polyethylene glycol derivative according to any one of claims 1 to 3, wherein the oligopeptide Z is an oligopeptide having at least one hydrophobic amino acid having a hydropathic index of 2.5 or more.

5. L 1 and L 2 are each independently a single bond, a urethane bond, an amide bond, an ether bond, a thioether bond, a secondary amino group, a urea bond, or an alkylene group containing such bonds and / or groups.

6. The branched degradable polyethylene glycol derivative according to any one of claims 1 to 5, wherein X is selected from the group consisting of an active ester group, an active carbonate group, an aldehyde group, an isocyanate group, an isothiocyanate group, an epoxy group, a maleimide group, a vinylsulfonyl group, an acryl group, a sulfonyloxy group, a carboxy group, a thiol group, a dithiopyridyl group, an α-haloacetyl group, an alkynyl group, an allyl group, a vinyl group, an amino group, an oxyamino group, a hydrazide group, and an azide group.

7. A branched degradable polyethylene glycol derivative represented by the following formula (2): [Case 2] (In the formula, k 1 and k 2 j is independently 1 to 12; 1 and j 2 are each independently 45 to 950, R is a hydrogen atom, a substituted or unsubstituted alkyl group having 1 to 4 carbon atoms, a substituted aryl group, an aralkyl group, or a heteroalkyl group, W is an oligopeptide having 5 to 47 residues and a symmetric structure centered on glutamic acid or lysine, a is 2 to 8, X is a functional group capable of reacting with a biologically relevant substance, and L 1 and L 2 are each independently a single bond or a divalent spacer.

8. 8. The branched degradable polyethylene glycol derivative according to claim 7, wherein the oligopeptide having a symmetric structure with glutamic acid or lysine as the center of W is an oligopeptide having the following structure w1 or w2: [C3] [C4] (wherein Q is a glutamic acid or lysine residue, and Z is a degradable oligopeptide of 2 to 5 residues consisting of neutral amino acids excluding cysteine.)

9. The branched degradable polyethylene glycol derivative according to claim 8, wherein the degradable oligopeptide Z is an oligopeptide having glycine as the C-terminal amino acid.

10. The branched degradable polyethylene glycol derivative according to any one of claims 8 to 9, wherein the degradable oligopeptide Z is an oligopeptide having at least one hydrophobic neutral amino acid having a hydropathic index of 2.5 or more.

11. L 1 and L 2 are each independently a single bond, a urethane bond, an amide bond, an ether bond, a thioether bond, a secondary amino group, a urea bond, or an alkylene group which may contain these bonds and / or groups.

12. The branched degradable polyethylene glycol derivative according to any one of claims 7 to 11, wherein X is selected from the group consisting of an active ester group, an active carbonate group, an aldehyde group, an isocyanate group, an isothiocyanate group, an epoxy group, a maleimide group, a vinylsulfonyl group, an acryl group, a sulfonyloxy group, a carboxy group, a thiol group, a dithiopyridyl group, an α-haloacetyl group, an alkynyl group, an allyl group, a vinyl group, an amino group, an oxyamino group, a hydrazide group, and an azide group.

Citation Information

Patent Citations

  • Progressive-response nano-self-assembled dendritic prodrug and preparation method and application thereof

    CN106421806A

  • Split-type degradable polymers and their composites

    JP2009527581A

  • Branched polyethylen glycol derivates comprising an acetal or ketal branching point

    WO2005108463A2

  • Polyoxyalkylene derivative

    WO2006088248A1

  • Degradable polyethylene glycol conjugate

    WO2019189853A1